brediwal õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - ivabradiin - õhukese polümeerikattega tablett - 5mg 14tk; 5mg 90tk; 5mg 98tk; 5mg 100tk; 5mg 250tk; 5mg 30tk; 5mg 84tk; 5mg 56tk; 5mg 28tk; 5mg 60tk
ivabradine actavis õhukese polümeerikattega tablett
actavis group ptc ehf. - ivabradiin - õhukese polümeerikattega tablett - 7,5mg 30tk; 7,5mg 90tk; 7,5mg 120tk; 7,5mg 28tk; 7,5mg 56tk; 7,5mg 98tk; 7,5mg 84tk; 7,5mg 60tk
bixebra õhukese polümeerikattega tablett
krka d.d. novo mesto - ivabradiin - õhukese polümeerikattega tablett - 7,5mg 112tk; 7,5mg 28tk; 7,5mg 30tk; 7,5mg 60tk; 7,5mg 14tk; 7,5mg 90tk; 7,5mg 180tk; 7,5mg 100tk
ivabradine mylan õhukese polümeerikattega tablett
mylan pharmaceuticals limited - ivabradiin - õhukese polümeerikattega tablett - 7,5mg 28tk; 7,5mg 56tk; 7,5mg 100tk
bixebra õhukese polümeerikattega tablett
krka d.d. novo mesto - ivabradiin - õhukese polümeerikattega tablett - 5mg 100tk; 5mg 98tk; 5mg 14tk; 5mg 90tk; 5mg 56tk; 5mg 112tk; 5mg 180tk; 5mg 60tk
ivabradine teva õhukese polümeerikattega tablett
teva b.v. - ivabradiin - õhukese polümeerikattega tablett - 5mg 100tk; 5mg 30tk; 5mg 60tk; 5mg 98tk; 5mg 28tk; 5mg 84tk; 5mg 112tk; 5mg 120tk
ivabradine mylan õhukese polümeerikattega tablett
mylan pharmaceuticals limited - ivabradiin - õhukese polümeerikattega tablett - 5mg 112tk; 5mg 100tk; 5mg 56tk; 5mg 98tk; 5mg 14tk
ivabradine grindeks õhukese polümeerikattega tablett
grindeks as - ivabradiin - õhukese polümeerikattega tablett - 5mg 56tk
ivabradine grindeks õhukese polümeerikattega tablett
grindeks as - ivabradiin - õhukese polümeerikattega tablett - 7,5mg 56tk
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastilised ained - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.